Key facts
- This page summarizes John S. Runyan's Form 4 filing for BIOLARGO, INC. (BLGO).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 05 Oct 2022, 20:17.
John S. Runyan - 03 Oct 2022 Form 4 Insider Report for BIOLARGO, INC. (BLGO)
- Reporting relationship
- Director
- Issuer ticker
- BLGO
- Reported as of
- 03 Oct 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Oct 2022, 20:17:09 UTC
- Prior SEC filing
- 05 Jul 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ John R. Browning, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
John S. Runyan filed Form 4 for BIOLARGO, INC. (BLGO) on 05 Oct 2022.
Change
- Previous filing in this sequence was filed on 05 Jul 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BLGO
transaction
Derivative
Option to Purchase Common Stock
Award
- Transaction value
- Shares
- +69,444
- Change %
- +2.5%
- Price
- Shares after
- 2,831,201
- Date
- 03 Oct 2022
- Ownership
- Direct
- Underlying class
- Common stock
- Underlying amount
- 69,444
- Exercise price
- $0.2700
- Footnotes
- F1, F2
BLGO
transaction
Derivative
Option to Purchase Common Stock
Award
- Transaction value
- Shares
- +23,750
- Change %
- +0.84%
- Price
- Shares after
- 2,854,951
- Date
- 03 Oct 2022
- Ownership
- Direct
- Underlying class
- Common stock
- Underlying amount
- 23,750
- Exercise price
- $0.2700
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
This Option was issued to Reporting Person as payment for $18,750 in fees due to Reporting Person by Issuer in exchange for services on its board of directors for the most recently completed quarterly period, pursuant to the Issuer's 2018 Equity Incentive Plan.
Footnote F2
The total reflects the October 2, 2022 expiration of options to purchase 47,500 shares of Issuer's common stock.
Footnote F3
This Option was granted to Reporting Person to replace an option that had been issued approximately 10 years ago to compensate Reporting Person for services to the Issuer and had recently expired unexercised due to a discrepancy between the original exercise price and current Issuer stock price, pursuant to plan adopted by the Issuer's Compensation Committee.